Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2010

View Archived Issues

Silver dihydrogen citrate antimicrobial shows preclinical efficacy in fungal infections

Chinese scientists claim new immunosuppressants

ArQule presents new FGFR-2 inhibitors

Spanish scientists discover new merosesquiterpenic derivatives with antitumor activity

MUSC Foundation for Research Development discloses new sphingosine kinase inhibitors

Phase I trial evaluates edotecarin plus 5-FU/leucovorin in advanced solid tumors

Clinical data disclosed on rituximab vs. cyclophosphamide in ANCA-associated vasculitis

Candesartan inhibits fibrosis in rat model of RMI by suppressing sFRP-2

Japanese scientists identify potential biomarkers for coronary artery disease

TM-38837 shows favorable safety and pharmacokinetics in healthy subjects

CTI files SPA with FDA for phase III pixantrone trial in non-Hodgkin's lymphoma

Curis identifies new inhibitors of PI3-kinase, mTOR and HDAC

Access Pharma advances thiarabine in hematological malignancies

Conditions for approval of Actemra for RA and pJIA lifted in Japan

ADXS-11-001 to enter phase II trial in cervical cancer in India

FDA clears Antisense Pharma's IND for trabedersen in high-grade glioma

EXC-001 reduces scar severity after abdominoplasty surgery in phase II trial

Idera raises funds to continue developing TLR-targeting agents

Five Prime and GSK join to discover drugs for skeletal muscle disorders

Shire subsidiary to acquire Movetis

Boston Scientific begins enrollment in EVOLVE trial of Synergy stent

Daiichi Sankyo initiates open offer for Zenotech Laboratories shares

Boceprevir meets primary endpoints in pivotal phase III trials in hepatitis C

PerkinElmer acquires VisEn Medical

Mipomersen lowers LDL-cholesterol in two phase III trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 1, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026